PAA Laboratories, founded in February 1988, specializes in the manufacture and worldwide distribution of cell culture products
for research, development, diagnostic and biopharmaceutical production. The company mantains high standards in its manufacturing
processes. As an example, PAA Laboratories is licensed to produce and offer cell culture reagents for in vivo cell culture use.
The most advanced facility of its kind in Europe will help PAA to become a highly qualified supplier to all customers active
in biologic vaccine and drug production, industrial in-vivo organ transplantation, tissue engineering and other critical fields.
Products and Services
PAA processes and manufactures animal and human sera, standard and cell line specific media for cell culture, serum and protein
free media, biochemical reagents and growth supplements. We also supply Bovine Serum Albumin (BSA) of different grades and
purity levels all used as vital nutrients in cell culture technology.
Our services also include the manufacturing of customized liquids and contract filling. The bottle, bag and container systems
are single use and designed for the transport and storage of liquids for a wide range of applications.
The core competence of PAA is the sourcing and processing of animal serum. PAA manufacturers Foetal Bovine Serum in Europe.
Due to the acquisition of GMP compliant manufacturing sites in North America and Australia we now serve a customer base world
wide. For all serum products we do have the capability to supply batch sizes up to 2600 litres. Extensive documentation for
full traceability (e.g. CoS, CoA, Veterinary Health Certificates, Batch Documentation) is available upon request.
All our products are manufactured in three GMP facilities based in Austria, Australia and Canada.
In 2003 PAA Laboratories inaugurated a new, state-of-the-art, FDA registered, GMP-compliant manufacturing plant outside of
Linz, Austria. This 5000 m3 pharmaceutical plant meets the most stringent US and European GMP regulations and is validated
according to the ICH guideline of the manufacture of Active Pharmaceutical Ingredients (APIs).
In 2005 PAA acquired the GMP production facilities of Cansera, Canada. The facility is strategically located close to the
Toronto International Airport and ideal for global distribution of serum and media products as well as ground and air transportation
throughout North America.
The 20,000 sq. ft. facility is registered with FDA for production of sterile sera and media products for IVD use as well as
contract production of sterile solutions. The North American facility that operates a completely segregated production suite
for BSE free origin serum products. The facility and segregation is monitored by CFIA and has been subject to inspection and
approval by USDA.
In Brisbane, Australia, PAA's operation includes integrated sourcing, collection, spinning and processing of raw bovine sera
into finished sterile products. The production suite is fully compliant under GMP and has both CIP and SIP systems. Shipping
of finished products directly from PAA Australia can be arranged.
PAA Laboratories Inc.
PAA Laboratories Ply Ltd